^
over1year
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (clinicaltrials.gov)
P1, N=64, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; This was a sponsor decision and was not a consequence of any safety concern
Trial termination • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
HER-2 negative
|
Tabrecta (capmatinib) • spartalizumab (PDR001) • lacnotuzumab (MCS110) • Ilaris (canakinumab) • ieramilimab (LAG525) • taminadenant (NIR178)
almost2years
Trial completion • Metastases
|
CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
BRAF wild-type • CD8 expression
|
Kisqali (ribociclib) • Tabrecta (capmatinib) • spartalizumab (PDR001) • Ilaris (canakinumab) • ieramilimab (LAG525)
2years
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (clinicaltrials.gov)
P1, N=64, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2022 --> Feb 2023 | Trial primary completion date: Oct 2022 --> Feb 2023
Trial completion date • Trial primary completion date • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
HER-2 negative
|
Tabrecta (capmatinib) • spartalizumab (PDR001) • lacnotuzumab (MCS110) • Ilaris (canakinumab) • ieramilimab (LAG525) • taminadenant (NIR178)
2years
Trial completion date • Metastases
|
CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
BRAF wild-type • CD8 expression
|
Kisqali (ribociclib) • Tabrecta (capmatinib) • spartalizumab (PDR001) • Ilaris (canakinumab) • ieramilimab (LAG525)
over2years
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (clinicaltrials.gov)
P1, N=64, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2022 --> Oct 2022 | Trial primary completion date: Jun 2022 --> Oct 2022
Trial completion date • Trial primary completion date • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
HER-2 negative
|
Tabrecta (capmatinib) • spartalizumab (PDR001) • lacnotuzumab (MCS110) • Ilaris (canakinumab) • ieramilimab (LAG525) • taminadenant (NIR178)
over2years
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. (PubMed, J Immunother Cancer)
Ieramilimab was well tolerated as monotherapy and in combination with spartalizumab. The toxicity profile of ieramilimab in combination with spartalizumab was comparable to that of spartalizumab alone. Modest antitumor activity was seen with combination treatment.
P1/2 data • Clinical Trial,Phase I • Clinical Trial,Phase II • Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
CD8 expression • LAG3 expression
|
spartalizumab (PDR001) • ieramilimab (LAG525)
over2years
PLATforM: Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (clinicaltrials.gov)
P2, N=196, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Jan 2023 --> Jun 2023 | Trial primary completion date: Aug 2022 --> Jan 2023
Enrollment closed • Trial completion date • Trial primary completion date
|
CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
BRAF wild-type • CD8 expression
|
Kisqali (ribociclib) • Tabrecta (capmatinib) • spartalizumab (PDR001) • Ilaris (canakinumab) • ieramilimab (LAG525)
almost3years
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (clinicaltrials.gov)
P1, N=64, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=220 --> 64 | Trial completion date: Jan 2022 --> Jun 2022 | Trial primary completion date: Jan 2022 --> Jun 2022
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
HER-2 negative
|
Tabrecta (capmatinib) • spartalizumab (PDR001) • lacnotuzumab (MCS110) • Ilaris (canakinumab) • ieramilimab (LAG525) • taminadenant (NIR178)
almost3years
PLATforM: Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (clinicaltrials.gov)
P2, N=195, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2022 --> Jan 2023 | Trial primary completion date: Dec 2021 --> Aug 2022
Clinical • Trial completion date • Trial primary completion date
|
CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
BRAF wild-type • CD8 expression
|
Kisqali (ribociclib) • Tabrecta (capmatinib) • spartalizumab (PDR001) • Ilaris (canakinumab) • ieramilimab (LAG525)
almost3years
Clinical • Trial completion • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • PGR expression
|
carboplatin • spartalizumab (PDR001) • ieramilimab (LAG525)
over3years
Clinical • Trial completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
carboplatin • spartalizumab (PDR001) • ieramilimab (LAG525)
almost4years
Clinical • Trial completion • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3)
|
LAG3 expression
|
spartalizumab (PDR001) • ieramilimab (LAG525)
over4years
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov)
Trial completion date: Jul 2020 --> Nov 2020 | Trial primary completion date: Jul 2020 --> Nov 2020
Clinical • Trial completion date • Trial primary completion date • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3)
|
LAG3 expression
|
spartalizumab (PDR001) • ieramilimab (LAG525)
over4years
PLATforM: Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (clinicaltrials.gov)
P2, N=195, Recruiting, Novartis Pharmaceuticals | Suspended --> Recruiting | Trial completion date: Aug 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Nov 2021
Clinical • Enrollment open • Trial completion date • Trial primary completion date • PD(L)-1 Biomarker
|
CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
BRAF mutation • CD8 expression
|
Kisqali (ribociclib) • Tabrecta (capmatinib) • spartalizumab (PDR001) • Ilaris (canakinumab) • ieramilimab (LAG525)
almost5years
Clinical • Trial completion date • Combination therapy • PD(L)-1 Biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
carboplatin • spartalizumab (PDR001) • ieramilimab (LAG525)
almost5years
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (clinicaltrials.gov)
P1, N=220, Recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2020 --> Jan 2022 | Trial primary completion date: Oct 2020 --> Jan 2022
Clinical • Trial completion date • Trial primary completion date • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
HER-2 negative
|
Tabrecta (capmatinib) • spartalizumab (PDR001) • lacnotuzumab (MCS110) • Ilaris (canakinumab) • ieramilimab (LAG525) • taminadenant (NIR178)
almost5years
Clinical • Enrollment closed • Combination therapy • PD(L)-1 Biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
carboplatin • spartalizumab (PDR001) • ieramilimab (LAG525)